Title

An Open-Label Trial of Aripiprazole Treatment in Dual Diagnosis Individuals: Safety and Efficacy

Authors

Authors

A. L. McRae-Clark; M. L. Verduin; B. K. Tolliver; R. E. Carter; A. E. Wahlquist; K. T. Brady; J. S. Cluver;S. Anderson

Comments

Authors: contact us about adding a copy of your work at STARS@ucf.edu

Abstract

This open-label study evaluated the safety and efficacy of aripiprazole in the treatment of 20 patients with co-morbid schizophrenia, schizoaffective disorder, or bipolar disorder and alcohol, cocaine, and/or marijuana use disorders. Primary outcomes were substance use, measured by the Timeline Followback, and score on the Clinical Global Impression scale for psychiatric and substance use symptoms. The data suggest that aripiprazole may reduce substance use and improve psychiatric symptoms in patients with co-morbid disorders; however, limitations are noted. Subsequent randomized studies are needed to further explore these findings.

Journal Title

Journal of Dual Diagnosis

Volume

5

Issue/Number

1

Publication Date

1-1-2009

Document Type

Article

First Page

83

Last Page

96

WOS Identifier

WOS:000283303200007

ISSN

1550-4263

Share

COinS